Main Logo
19th Annual International Myeloma Society Meeting
Lenalidomide, Bortezomib, and Dexamethasone Plus AHSCT Leads to Significant PFS Improvement in Myeloma
Leah SherwoodMyeloma | November 16, 2022
The data were from the phase III DETERMINATION trial...
Read More
Carfilzomib, Lenalidomide, and Dexamethasone Improve PFS Over Lenalidomide in Post-AHSCT Myeloma
Leah SherwoodMyeloma | November 16, 2022
Carfilzomib, lenalidomide, and dexamethasone improved progression-free survival (PFS) over...
Read More
Oral Triplet Regimen Performs Better Than Doublet in Patients with Myeloma Progressing on Frontline Lenalidomide
Cecilia BrownMeeting News | November 22, 2022
Adding ixazomib to pomalidomide and dexamethasone improved progression-free survival rates...
Read More

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    Editorial Board

    About Us

    Terms of Use

    Advertising

    Privacy Policy

    Editorial Policy

    Our Network

    MashupMD

    GU Oncology Now

    Cancer Nursing Today

    Urban Health Today

    DocWire News

    Connect

    eNewsletters

    Calendar of Events

    Contact Us

    Contribute

    Formedics logo© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |